Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation

Publication
Article

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation. This study seeks to enhance early prediction of patient outcomes through the monitoring of 92 proteins immediately after transplantation and 2 weeks post-transplantation.

The study found that patients who later developed acute graft versus host disease exhibited lower levels of IL18-R1, LIF-R, and IL22-RA1. Conversely, those who experienced chronic GvHD displayed lower levels of CD244, TSLP, IL15-RA, and IL-33. Higher levels of seven inflammatory proteins—CD244, LIF-R, FGF21, IL10-RB, HGF, CD40, and TNFRSF9—were linked to an increased risk of disease relapse. This underscores the importance of dynamic monitoring of inflammatory responses to better predict and potentially mitigate post-transplant complications.

These findings emphasize the potential role of specific proteins and their receptors in alloreactive immunity and suggest a link between baseline inflammatory profiles and treatment outcomes. The trajectory of change in protein concentrations provides a strong indication of the risk of GvHD or relapse, indicating a strategic approach to patient monitoring that could lead to personalized care. Despite its limitations, such as the need for validation in larger cohorts, this study marks a significant step toward the utilization of early post-transplant biomarkers for predicting clinical outcomes.

Reference

Verma K, Croft W, Greenwood D, et al. Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation. Front Immunol. 2024;14:1332777. Published 2024 Jan 3.

https://doi.org/10.3389/fimmu.2023.1332777

Recent Videos
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Related Content